



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

DEC 22 2000

George H. Scherr, Ph.D.  
Director  
ADRI/Technam  
350 East Sauk Trail  
South Chicago Heights, Illinois 60411

Re: K003134  
Trade Name: Foam Calcium Alginate Topical Wound Dressing  
Regulatory Class: Unclassified  
Product Code: KMF  
Dated: October 2, 2000  
Received: October 6, 2000

Dear Dr. Scherr:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - George H. Scherr, Ph.D.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): K003134Device Name: FOAM CALCIUM ALGINATE TOPICAL WOUND DRESSING

Indications For Use:

CALGITROL calcium alginate wound dressings with maltodextrin may be utilized for exudating or potentially exudating wounds such as dermal lesions or injuries, superficial cuts and wounds, dermal ulcer, or pressure sores, and Stage IV wounds.

CALGITROL calcium alginate wound dressings with maltodextrin are indicated for the ~~the~~ treatment of all medium to heavily exudating wounds; for example

- ulcers of the leg
- pressure sores
- chronic wounds
- first and second-degree burns
- donor sites

CALGITROL calcium alginate wound dressings with maltodextrin when in contact with an exudate from a wound will form a soft colloidal gel which covers the wound, protects it, and thereby enhances the formation of granulation tissue in subsequent healing.

CALGITROL calcium alginate wound dressings with maltodextrin should not be used for ulcers resulting from infection, lesions in patients with active vasculitis or third degree burns. CALGITROL calcium alginate wound dressings are not intended for surgical implantation.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF  
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

7/10/96  
(Division Sign-Off)

Division of General Restorative Devices

510(k) Number K003134

Prescription Use X  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_

(Optional Format 1-2-96)